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Abstract
Background: The α1‐adrenoceptor agonist, phenylephrine, is used at high concen-
trations as a mydriatic agent and for the treatment of nasal congestion. Among its 
adverse side‐effects transient burning sensations are reported indicating activation of 
the trigeminal nociceptive system.
Methods: Neuropeptide release, calcium imaging and meningeal blood flow record-
ings were applied in rodent models of meningeal nociception to clarify possible re-
ceptor mechanisms underlying these pain phenomena.
Results: Phenylephrine above 10 mM dose‐dependently released calcitonin gene‐re-
lated peptide (CGRP) from the dura mater and isolated trigeminal ganglia, whereas 
hyperosmotic mannitol at 90 mM was ineffective. The phenylephrine‐evoked release 
was blocked by the transient receptor potential vanilloid 1 (TRPV1) antagonist BCTC 
and did not occur in trigeminal ganglia of TRPV1‐deficient mice. Phenylephrine at 
30 mM caused calcium transients in cultured trigeminal ganglion neurons responding 
to the TRPV1 agonist capsaicin and in HEK293T cells expressing human TRPV1. 
Local application of phenylephrine at micromolar concentrations to the exposed rat 
dura mater reduced meningeal blood flow, whereas concentrations above 10  mM 
caused increased meningeal blood flow. The flow increase was abolished by pre‐ap-
plication of the CGRP receptor antagonist CGRP8‐37 or the TRPV1 antagonist BCTC.
Conclusions: Phenylephrine at high millimolar concentrations activates TRPV1 re-
ceptor channels of perivascular afferents and, upon calcium inflow, releases CGRP, 
which increases meningeal blood flow. Activation of TRPV1 receptors may underlie 
trigeminal nociception leading to cranial pain such as local burning sensations or 
headaches caused by administration of high doses of phenylephrine.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2019 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation - EFIC®
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1 |  INTRODUCTION
Phenylephrine is a sympathomimetic drug acting as a specific 
α1‐adrenoceptor agonist. It is clinically used at low doses 
(50–100 µg) for the treatment of hypotension during spinal, 
epidural and general anaesthesia (Heesen, Kölhr, Rossaint, 
& Straube, 2014; Poterman et al., 2015). The blood pres-
sure normalizing effect of phenylephrine is mainly caused 
by vasoconstriction through the activation of α1‐adrenocep-
tors (Reid, 1986). Phenylephrine at high doses (1%–5%, i.e. 
60–300 mM) is locally used as a mydriatic agent, for example 
in the treatment of glaucoma (McAuliffe‐Curtin & Buckley, 
1989; Moisseiev et al., 2015). As adverse side‐effects of this 
treatment increases in blood pressure and pulse rate (Chin, 
Law, & Chin, 1994) and bronchoconstriction in premature in-
fants (Kim, Choi, & Kwak, 2015) have been reported. For the 
treatment of nasal congestion high local doses (up to 4 mg) 
of phenylephrine have long been used (Myers & Iazzetta, 
1982), and later trials have been published to replace the in-
tranasal application by oral phenylephrine (Kollar, Schneider, 
Waksman, & Krusinska, 2007; Meltzer, Ratner, & McGraw, 
2015). Oral doses of up to 30 mg were not different to placebo 
regarding nasal congestion but a small percentage of patients 
responded with headaches (Meltzer et al., 2015). Another, so 
far unexplained, local adverse side‐effect is a painful, burn-
ing sensation induced by phenylephrine‐containing eye drops 
(Moisseiev et al., 2015) or nasal spray as mentioned in med-
ical information (https ://medli neplus.gov/drugi nfo/meds/
a6160 49.html), which can hardly be explained by the known 
α1‐adrenoceptor agonist effects of phenylephrine.
The rationale to investigate the effects of phenylephrine 
on meningeal blood flow in rodents was derived from ear-
lier experiments, in which we used phenylephrine to study 
the mechanisms underlying increases in blood flow concom-
itant with temperature changes in the dura mater (Holom, 
Messlinger, & Fischer, 2008). We recognized an unexpected 
effect of phenylephrine, that is it rather potentiated vasodila-
tation, which is usually associated with pronociceptive effects 
in the trigemino‐vascular system. The trigemino‐vascular 
system is the functional unit of intracranial blood vessels 
and their trigeminal innervation. In this study we therefore 
localized α1‐adrenoceptors with immunohistochemistry and 
probed their possible role using measurement of neuropeptide 
release, calcium imaging and recording of vascular responses 
over a wide range of phenylephrine concentrations in the tri-
gemino‐vascular system of rodents. In view of the mentioned 
temperature experiments (Holom et al., 2008) we addressed 
the most important transduction channels expressed in no-
ciceptive neurons, the family of transient receptor potential 
(TRP) channels, which may be involved in trigeminal noci-
ception activated by high‐dose phenylephrine.
TRP receptor channels of the vanilloid type 1 (TRPV1) 
have been intensely studied for more than two decades in the 
spinal and the trigeminal system (Nagy, Sántha, Jancsó, & 
Urbán, 2004). They are essential for heat transduction ex-
pressed in most of the slowly conducting nociceptive affer-
ents (Dux, Sántha, & Jancsó, 2012; Julius, 2013; Numazaki 
& Tominaga, 2004). TRP receptor channels of the ankyrin 
type (TRPA1) have been associated with noxious cold trans-
duction, although the matter is not yet entirely clear (Zygmunt 
& Högestätt, 2014). TRP receptor channels of the melastatin 
type 8 (TRPM8) have also been associated with cold trans-
duction (Babes, Ciobanu, Neacsu, & Babes, 2011) and are es-
pecially interesting for trigeminal nociception, because they 
show genetic variants in migraine families (Dussor & Cao, 
2016). All three TRP receptor channel types are also activated 
by a variety of endogenous metabolic products and/or de-
signed chemical substances determining the chemosensitive 
properties of polymodal nociceptors (Gerhold & Bautista, 
2009; Stucky et al., 2009). Finally, a significant population of 
TRP expressing afferents are peptidergic containing the va-
soactive calcitonin gene‐related peptide (CGRP) or substance 
P, and all three TRP channels are conductive for calcium and 
could therefore directly or indirectly be involved in vasomo-
tor responses upon their activation (Earley & Brayden, 2015). 
Therefore, we focused on these TRP receptor channel types as 
a possible alternative target for phenylephrine at high doses.
2 |  METHODS
All experiments were done in accordance with the ethical 
guidelines of the International Association for the Study of 
Pain and in compliance with the guidelines for the welfare 
of experimental animals of the Federal Republic of Germany 
and the European Commission (Directive 2010/63/EU). All 
Significance: Phenylephrine is used at high concentrations as a mydriaticum and for 
treating nasal congestion. As adverse side‐effects burning sensations and headaches 
have been described. Phenylephrine at high concentrations causes calcium transients 
in trigeminal afferents, CGRP release and increased meningeal blood flow upon 
activation of TRPV1 receptor channels, which is likely underlying the reported pain 
phenomena.
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animals were bred and housed in the animal facility of our 
Institute at a 12/12  hr  day–night cycle. The experimental 
protocol for in vivo experiments was reviewed by an ethics 
committee and approved by the local district government of 
Unterfranken.
2.1 | Immunohistochemistry of trigeminal 
ganglion and dura mater
Adult male and female Wistar rats (body weight 300–450 g) 
deeply anaesthetized by inhaling 5% isoflurane and i.p. in-
jection of thiopental (Trapanal®, Byk Gulden, Germany, 
150–200  mg/kg) were thoracotomized and perfused tran-
scardially with physiological saline followed by 4% para-
formaldehyde in 0.1  M phosphate buffer (pH 7.4). After 
removal of the skin, the skull was divided into halves along 
the midline and the cerebral hemispheres were removed. 
Trigeminal ganglia were carefully excised from the Meckel's 
cave, stored in phosphate‐buffered saline (PBS; 0.01 M, pH 
7.4) overnight and transferred into 30% sucrose for another 
day, then quickly frozen at −20°C. From the frozen blocks 
sections of 14  µm were cut with a cryotome and mounted 
on glass slides. For indirect immunofluorescence, the fixed 
sections were rinsed in PBS, pre‐incubated for 1 or 2 hours 
at room temperature with a solution of 5% donkey serum 
(Dianova, Hamburg, Germany), 0.5% Triton X‐100 and 1% 
bovine serum albumin in PBS, rinsed in PBS and incubated 
overnight with polyclonal rabbit antiserum raised against 
α1‐adrenergic receptors (Sigma A270, 1:100) and goat an-
tiserum raised against rat CGRP (Biotrend BT‐17–2090–07, 
1:10). To control the specificity of immunostaining, one slide 
was prepared without first antibodies. Then the slides were 
washed with PBS, incubated with donkey anti‐rabbit Alexa 
488 (Molecular Probes A21 206, 1:100) and donkey anti‐goat 
Alexa 555 (Molecular Probes A21 432, 1:1,000) secondary 
antibodies for 1 hour at room temperature, rinsed in PBS and 
coverslipped in Fluoromount G (Science Services, München, 
Germany). Some samples were mounted with Roti®‐Mount 
Fluor Care (Roth, Karlsruhe, Germany) containing 4′,6‐di-
amidin‐2‐phenylindol (DAPI) for nuclear DNA staining.
Samples of the dura mater of rats were carefully dis-
sected and processed without fixation to preserve optimal 
immunoreactivity. The whole mounts were immunostained 
similarly as the ganglion sections while they were kept float-
ing in the solutions. They were incubated overnight at 4°C 
with goat antiserum raised against α1A‐adrenergic recep-
tors (Santa Cruz sc‐1477, 1:50) and mouse antiserum raised 
against smooth muscle actin (SMA; Sigma 2,547, 1:100). 
Small parts of dura mater were processed without first an-
tibodies for control. Then the whole mounts were washed 
and incubated with donkey anti‐goat Alexa 488 (Molecular 
Probes A11055, 1:1,000) and donkey anti‐mouse Alexa 555 
(Molecular Probes A31570, 1:1,000) secondary antibodies.
The immunostained samples were analysed using a LSM 
780 light and confocal microscope (Carl Zeiss MicroImaging 
GmbH, Jena, Germany) mounted on an inverted Axio 
Observer Z1. Two dry objective lenses (10 x and 20 x with 
numerical apertures of 0.3 and 0.8) were used. Fluorescent 
structures were observed in the light path mode using red and 
green filters. Confocal images were taken using filter settings 
for Alexa 488 and 555. The numbers of image pixels were 
1,024 x 1,024 or 512 x 512, and pictures were converted to 
a 12‐bit RGB tiff‐file using confocal assistant software ZEN 
2010.
2.2 | Measurement of CGRP release
Adult Wistar rats (250–420 g) and C57BL/6 mice (21–30 g) 
of either sex as well as mice with genetically deleted TRPV1 
receptor channels (TRPV1‐/‐) bred on the background of 
C57BL/6 (22–28 g) were killed by CO2 inhalation and decap-
itated. After removal of the skin, the skull was divided into 
halves along the midline and the cerebral hemispheres were 
removed. Skull halves with intact dura mater were washed at 
room temperature for 30 min with synthetic interstitial fluid 
(SIF, see below). The halves were placed in a humid chamber 
and maintained at 37°C. The cranial fossae were filled with 
500 µl (rat) or 200 µl (mice) solution. From skull halves of 
other mice the trigeminal ganglia were dissected and trans-
ferred into wells filled with 200 µl SIF. Vehicle (SIF) was 
always the first solution, consecutively replaced by solutions 
of phenylephrine or antagonists in SIF as specified in the 
results. Solutions were collected at periods of 5 or 10 min 
by carefully removing the content of the skull halves or the 
wells with a micropipette. All samples were transferred to 
Eppendorf cups and 100 µl of each sample were taken, di-
luted with 25 µl enzyme immunoassay (EIA) buffer (SPIbio, 
Paris, France) and immediately frozen at −20°C for subse-
quent analysis. CGRP content of the samples was measured 
using a specific CGRP‐EIA kit (SPIbio, Paris, France). The 
absorbance of the reaction product representing the CGRP 
concentration of the sample was determined photometrically 
using a microplate reader (Opsys MR, Dynex, Denkendorf, 
Germany). The minimum detection limit of the assay is spec-
ified as 5 pg/ml by the manufacturer. The CGRP concentra-
tion was calculated in pg/ml.
2.3 | Calcium imaging of trigeminal 
neurons and HEK293T cells
Adult C57BL/6 wild‐type and TRPV1‐/‐ mice (body weight 
21–28 g, both sexes) were used and prepared as for CGRP 
release. Trigeminal ganglia (TG) were excised, exposed 
to collagenase and protease (Sigma‐Aldrich, Taufkirchen, 
Germany) before mechanical dissociation, plated on poly‐D‐
lysine‐coated coverslips and cultured in serum‐free neuronal 
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medium supplemented with 100 ng/ml mouse nerve growth 
factor (NGF, Alomone Labs, Israel). After 1‐day incubation 
at 37°C and 5% CO2, cells were stained by 3 µM Fura‐2‐AM 
and 0.02% pluronic (Invitrogen, St. Leon Rot, Germany). 
HEK293T cells were regularly passaged and controlled for 
mycoplasma contamination and were transiently transfected 
with plasmids containing human TRPV1 (hTRPV1) using 
jetPEI transfection reagent from Polyplus Transfection 
(Illkirch, France). Cells were plated onto poly‐D‐lysine‐
coated glass coverslips and used for experiments within 
24  hr. Coverslips were mounted on an inverse microscope 
and constantly superfused with extracellular fluid (EF, see 
below) used as vehicle by a gravity‐driven common‐outlet 
superfusion. Solutions were applied via different lines running 
at the same flow rate; this ensured mixing within the common 
outlet about 1  second before the solution reaches the cells. 
Fluorescence evoked by illumination at 340 nm and 380 nm 
was acquired by a 12‐bit CCD camera (Imago Sensicam QE, 
Till Photonics) system with a monochromator (Polychrome 
V, Till Photonics) coupled to an Olympus IX71 microscope, 
using the TILLvisION 4 (Till Photonics) software package. 
After background subtraction the 340/380  nm ratio time 
series were calculated for individual cells, the mean ± SEM 
was visualized. The cellular response to phenylephrine and 
other consecutively applied substances dissolved in vehicle 
was calculated as the percentage change in fluorescence ratio 
(i.e. the maximal change in ratio during the stimulus to the 
baseline ratio under vehicle before the stimulus, ΔR/R0). A 
value larger than 0.2 (20% increase in ratio) was considered 
as a response.
2.4 | Meningeal blood flow recordings
Wistar rats of both sexes (body weights of 250–350 g) were 
anaesthetized with increasing concentrations of isoflurane 
(up to 5%, Forene, Abbott, Wiesbaden, Germany) inhaled 
in a closed box, continued by application of 2% isoflurane 
through a tight mask. Atropine sulphate (Braun Melsungen 
AG, Melsungen, Germany, 0.5  mg/ml, 1:10 in saline) was 
injected subcutaneously at 1  ml/kg to prevent salivation. 
Femoral artery and vein were cannulated for recording of 
blood pressure and intravenous (i.v.) infusion of substances. 
The animals were tracheotomized to be artificially ventilated 
with a mixture of oxygen‐enriched room air and 2% isoflu-
rane. Depth of anaesthesia was routinely assessed and held 
at a level in which noxious stimuli (pinching of earlobes) 
failed to elicit motor reflexes or changes in systemic arterial 
pressure. The body temperature of the animals was recorded 
by a thermoprobe inserted into the rectum and was kept at 
37–37.5°C with a feedback‐controlled heating pad. Systemic 
blood pressure was recorded with a pressure transducer con-
nected to the catheter inserted into the right femoral artery. 
The expiratory CO2 was continuously monitored (Artema 
MM 200, Karl Heyer, Bad Ems, Germany) and maintained at 
3%–3.5%. The head of the animal was fixed in a stereotaxic 
frame and held by ear bars and a snout clamp. The eyes were 
covered with dexpanthenol ointment (Bepanthen®, Bayer 
Vital GmbH, Leverkusen, Germany) to prevent dehydration 
of the cornea. A median incision was made along the midline 
of the scalp, the periosteum was moved aside and, either on 
one or on both sides, a cranial window of about 8 x 6 mm was 
drilled into the parietal bone under saline rinsing to expose 
the cranial dura mater.
The exposed dura mater in the cranial windows was cov-
ered by SIF. For chemical stimulation, the SIF was replaced 
by 40 µl of solutions. Needle type probes of a laser Doppler 
flowmeter (DRT4, Moor Instruments, Axminster, UK) were 
positioned over branches of the middle meningeal artery sup-
plying the dura mater. Blood flow was recorded at a sampling 
rate of 10 Hz and expressed in arbitrary perfusion units (PU). 
The systemic blood pressure was recorded simultaneously. 
Data were stored and processed with the MoorSoft program 
for Windows. The basal blood flow was the mean flow value 
measured during a 3 min period prior to the stimulation of the 
dura mater. Blood flow values during stimulation were as-
sessed as mean values measured during the 5 min application 
period and compared to the respective basal flow measured 
prior to stimulation. The experiment was terminated by i.v. 
application of an overdose of thiopental.
2.5 | Substances
Synthetic interstitial fluid (SIF) contained (in mM) 107.8 NaCl, 
26.2 NaHCO3, 9.64 Na‐gluconate, 7.6 sucrose, 5.55 glucose, 
3.5 KCl, 1.67 NaH2PO4, 1.53 CaCl2 and 0.69 MgSO4and was 
buffered to pH 7.4 with carbogen gas (95% O2, 5% CO2). 
Mannitol (D‐mannitol, Carl Roth, Karlsruhe, Germany) was 
freshly dissolved in SIF. Extracellular fluid (EF) for calcium 
imaging was composed of (in mM): NaCl 140, KCl 4, CaCl2 
1.25, MgCl2 1, Glucose 5, Hepes 10). Phenylephrine (Sigma‐
Aldrich, Taufkirchen, Germany) was prepared as a stock 
solution of 100 mM (pH 7.4) in SIF or in EF (for calcium 
imaging) and phentolamine (Sigma‐Aldrich, Taufkirchen, 
Germany) as a stock solution of 10  mM in aqua destillata 
and further diluted with SIF or EF to the final concentrations 
(pH 7.4). HC030031 (1,2,3,6‐Tetrahydro‐1,3‐dimethyl‐N‐[4‐
(1‐methylethyl)phenyl]‐2,6‐dioxo‐7H‐purine‐7‐acetamide, 
2‐(1,3‐Dimethyl‐2,6‐dioxo‐1,2,3,6‐tetrahydro‐7H‐
purin‐7‐yl)‐N‐(4‐isopropylphenyl)acetamide) and BCTC 
(4‐(3‐Chloro‐2‐pyridinyl)‐N‐[4‐(1,1‐dimethylethyl)
phenyl]‐1‐piperazinecarboxamide) were acquired from 
Sigma‐Aldrich, Taufkirchen, Germany and prepared as stock 
solutions of 10 mM in DMSO (HC 030,031) or SIF (BCTC). 
CGRP8‐37 (Bachem, Biochemica, Heidelberg, Germany) 
was dissolved in saline and stored frozen as aliquots of 
100  µM. Capsaicin and allyl isothiocyanate (AITC) from 
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Sigma‐Aldrich, Taufkirchen, Germany were prepared as 
stock solutions of 10 mM and 1 M, respectively, in ethanol, 
WS‐12 (Cyclohexanecarboxamide,N‐(4‐methoxyphenyl)‐5‐
methyl‐2‐(1‐methylethyl)) from Santa‐Cruz (Heidelberg, 
Germany) as a stock solution of 50 mM in DMSO. All stock 
solutions were kept deep‐frozen, defrosted and diluted with 
saline or SIF to the respective concentrations immediately 
before they were used.
2.6 | Biometry and statistics
Prior to main experiments, pilot experiments were performed 
to calculate the power for statistically evaluable group sizes 
of CGRP release and blood flow data, as specified in the re-
sults. For calcium imaging, group sizes were not designed 
a priori, rather we tested a maximum of neurons identified 
in the cultures. Ganglia of two animals each were pooled to 
dissociate sufficient numbers of neurons distributed to 4–6 
culture dishes. For CGRP release experiments phenylephrine 
and vehicle were tested in parallel using paired hemisected 
skulls or ganglia, respectively. EIA processing was done by 
a researcher blinded to the parameters of the release experi-
ments. For blood flow measurements multiple substances 
were applied in a randomized order. Statistical analysis was 
performed using Statistica software (StatSoft, Tulsa, USA). 
For comparing blood flow values before and after application 
of substances, two‐tailed Student's t‐test was used after test-
ing for normal distribution (Shapiro–Wilk's test); if normal-
ity failed, the non‐parametric Wilcoxon matched pairs test 
was used. One‐ and two‐way analysis of variance (ANOVA) 
extended by Tukey's honest significant test, the Fisher's exact 
probability test and product‐moment correlations were used 
as specified in the Results. The level of significance was set 
at p < .05. Data were normalized to baseline as specified and 
are presented as mean values ± standard error of the mean 
(SEM).
3 |  RESULTS
3.1 | Immunohistochemistry of α1‐
adrenoceptors
In order to figure out possible binding sites of phenylephrine in the 
trigeminovascular system, we applied immunohistochemistry 
using rat trigeminal ganglion sections and the cranial dura 
mater. In addition to single immunostaining, we combined 
immunostaining of α1‐adrenoceptor protein with CGRP in the 
ganglion as a marker for peptidergic neurons, and in the dura 
mater we combined α1A‐adrenoceptor protein immunostaining 
with that of SMA as a marker for vascular smooth muscles. In 
20 sections of 5 trigeminal ganglia we counted 6,732 neurons. 
Among them a small fraction (12.5 ± 1.5%) of mostly small and 
middle sized neurons was immunopositive for α1‐adrenoceptor 
protein (Figure 1a‐c). However, combined immunolabelling 
showed that there was virtually no co‐staining with CGRP‐
immunoreactivity. In the dura mater immunostaining for 
α1A‐adrenoceptors was mainly seen in the wall of arteries and 
precapillary arterioles, co‐localized or closely associated with 
SMA immunoreactivity that outlined circular musculature 
(Figure 1d‐e). Veins showed network‐like SMA staining 
but nearly no α1A‐adrenoceptor immunoreactivity. Some 
perivascular nerve fibres appeared immunopositive for α1A‐
adrenoceptor protein, the most characteristic receptor subtype 
expressed in primary sensory neurones (Nicholson, Dixon, 
Spanswick, & Lee, 2005). Trigeminal ganglion sections and 
dura mater not incubated with primary antisera showed no 
specific immunostaining indicating that secondary antibodies 
did not directly bind to any structure in these tissues.
F I G U R E  1  Immunohistochemistry 
in rat trigeminal ganglion (a‐c) and dura 
mater (d‐e). Some trigeminal ganglion 
neurons of middle and small sizes show 
immunoreactivity for α1‐adrenoceptor 
protein (green), whereas CGRP 
immunoreactive neurons (red) are mostly 
small and more frequent. Neurons with 
both markers were not observed. In the dura 
mater α1A‐adrenoceptor immunoreactivity 
is seen in some perivascular nerve fibres 
(green arrows) apart from large and small 
arterial (AV) and venous vessels (VV), 
which show also immunoreactivity for 
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3.2 | CGRP release from dura mater and 
trigeminal ganglion
Assuming that phenylephrine may dose‐dependently re-
lease CGRP from meningeal afferents, we first made a 
small series of pilot experiments (n = 4) challenging me-
ninges in the rat hemisected preparation with phenylephrine 
at logarithmic dose steps (10 µM–100 mM) and periods of 
5 min. Phenylephrine up to 10 mM did not increase CGRP 
release but 100  mM was followed by a more than three-
fold increase compared to baseline under superfusion with 
vehicle (SIF). To control if the high molar concentration 
of phenylephrine is responsible for the CGRP release, in 
6 experiments mannitol at 90  mM was applied followed 
by SIF, phenylephrine (30 mM) and finally KCl (60 mM). 
Mannitol did not cause CGRP release (100.8 ± 10.1% of the 
baseline), whereas the CGRP release after phenylephrine 
tended to increase (156.0 ± 28.8%) and was significantly 
higher after KCl (491.8 ± 91.8%) compared to baseline (re-
peated measures ANOVA, F4,20 = 19.1, p <  .001; Tukey 
HSD post hoc test, p < .001) (Figure 2a).
Next we tested meningeal CGRP release with substance 
application at periods of 10 min, which turned out to be more 
effective than 5 min. There was again no difference between 
phenylephrine at 10 mM and vehicle (SIF), whereas applica-
tion of phenylephrine at 100 mM was followed by an increase 
in release to 369.4  ±  38.8% of the SIF baseline (n  =  8). 
Interestingly, the subsequent application of depolarizing KCl 
(60 mM) was no longer effective in releasing CGRP (Figure 
2b). In parallel control experiments (n = 5), repetitive appli-
cation of SIF showed no significant CGRP releasing effect, 
whereas KCl at the end caused a more than 10‐fold CGRP 
release compared to baseline. The effects of phenylephrine at 
100 mM and KCl are statistically robust (two‐way repeated 
measures ANOVA, F3,33 =  58.2 for sequence and 92.9 for 
groups; unequal n HSD post hoc test, p  <  .001). Finally, 
application of phenylephrine at 30 mM in a separate set of 
experiments (n = 6) was followed by an increase in CGRP re-
lease to 283.5 ± 57.2% of the SIF baseline (repeated measures 
ANOVA, F2,8 = 11.4; Tukey HSD post hoc test, p < .05). The 
response to the subsequent 60 mM KCl application was at-
tenuated (184.2 ± 52.2%) and was not significantly different 
from baseline (p < .06). Thus, there is dose‐dependent CGRP 
release within a narrow window of efficacy at high doses of 
phenylephrine, whereas the response to subsequent KCl ap-
plication seems to be suppressed depending on the effect of 
pre‐applied phenylephrine (Figure 2c).
Since the pattern of phenylephrine‐evoked CGRP re-
lease was reminiscent of the effect of agonists operating at 
TRP channels, we next tested if HC030031, an antagonist 
F I G U R E  2  CGRP release from the cranial dura mater in 
the hemisected rat head ex vivo. (a) CGRP release (mean ± SEM) 
after synthetic interstitial fluid (SIF), mannitol (Ma) 90 mM, again 
SIF, phenylephrine (Phe) 30 mM and finally KCl (60 mM) applied 
successively at 5 min intervals. (b) CGRP release (mean ± SEM) after 
10 and 100 mM phenylephrine or repetitive SIF and KCl applied at 
10 min intervals. (c) CGRP release normalized to baseline (SIF) after 
10, 30 and 100 mM phenylephrine and 60 mM KCl applied for 10 min 
each. Data were compared using repeated measures ANOVA followed 
by the Tukey HSD post hoc test (a and c) or two‐way repeated 
measures ANOVA and unequal n HSD post hoc test (b);* significant 
difference to baseline (SIF)
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at TRPA1 receptors, or BCTC, an antagonist at TRPV1 re-
ceptors, modulates CGRP release in the same preparation. 
Superfusion of HC030031 (50  µM) itself did not influ-
ence CGRP release. After application of phenylephrine at 
100 mM together with HC030031, the CGRP release was 
approximately 5.5‐times over baseline, that is higher than 
in the previous experiments without HC030031 (n  =  6, 
repeated measures ANOVA and Tukey HSD test, F3,15 
= 112.4; Tukey HSD post hoc test, p < .001 for HC030031/
phenylephrine), whereas the subsequent application of KCl 
(60  mM) was rather ineffective (Figure 3a). Superfusion 
with BCTC (10  µM) did not cause CGRP release, how-
ever, it almost completely abolished the releasing effect of 
100 mM phenylephrine (n = 6, repeated measures ANOVA, 
F3,15 = 62.7; Tukey HSD post hoc test, p = .046 for BCTC/
phenylephrine). Remarkably, the subsequent KCl applica-
tion was also ineffective (Figure 3a). This result pointed to 
TRPV1 but not TRPA1 receptor channels involved in the 
CGRP releasing effect of phenylephrine.
To confirm this hypothesis, we employed the same he-
misected cranial preparation in the mouse measuring CGRP 
release from the dura mater at 10 min intervals (Figure 3b). 
Since the mouse dura is more sensitive compared to the rat 
dura, we used phenylephrine at 30 mM and KCl at 40 mM. 
In C57BL/6 wild‐type mice, phenylephrine was followed 
by a more than fourfold increase in CGRP release com-
pared to baseline (SIF), whereas the CGRP releasing effect 
of the subsequent KCl superfusion was attenuated to 1.6‐
fold the baseline, which was not significantly different from 
baseline (n = 6, repeated measures ANOVA, F2,10 = 18.5; 
Tukey HSD post hoc test, p < .001 for phenylephrine and 
p  =  .37 for KCl). In mice lacking functional TRPV1 re-
ceptor channels (TRPV1‐/‐) phenylephrine 30 mM was in-
effective but KCl caused a more than twofold increase in 
CGRP release (n  =  8, repeated measures ANOVA, F2,14 
= 175.1; Tukey HSD post hoc test, p = .46 for phenyleph-
rine and p < .001 for KCl).
This result was largely confirmed in isolated mouse 
trigeminal ganglia (Figure 3c). In ganglia from C57BL/6 
mice after phenylephrine at 30 mM the CGRP release was 
significantly increased but, different to the dura, simi-
larly high values were measured after the subsequent KCl 
(40  mM) application (repeated measures ANOVA, F2,6 
= 30.9; Tukey HSD post hoc test, p < .005 for phenyleph-
rine and p < .001 for KCl). In TRPV1‐/‐ mice, phenyleph-
rine at 30  mM was not followed by a significant CGRP 
release, whereas KCl was effective (n = 6, repeated mea-
sures ANOVA, F2,10 =  88.2; Tukey HSD post hoc test, 
p = .93 for phenylephrine and p < .001 for KCl).
F I G U R E  3  CGRP release from the cranial dura mater of rat 
(a) and mouse (b) as well as isolated trigeminal ganglia of mouse 
(c) determined at 10 min intervals, mean values ± SEM. (a) CGRP 
release at baseline (SIF), after application of the TRPA1 antagonist 
HC030031 (50 µM) or the TRPV1 antagonist BCTC (10 µM) followed 
by phenylephrine (100 mM) and KCl (60 mM). (b) CGRP release from 
C57BL/6 wild‐type and TRPV1‐/‐ mice dura mater after phenylephrine 
(30 mM) and KCl (40 mM). (c) CGRP release from C57BL/6 wild‐
type and TRPV1‐/‐ mice ganglia after phenylephrine (30 mM) and 
KCl (40 mM). Data were compared using repeated measures ANOVA 
followed by the Tukey HSD post hoc test; * significant difference to 
baseline (SIF)
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3.3 | Calcium imaging
To further test if the CGRP release upon high‐dose 
phenylephrine is due to calcium inflow through TRP receptor 
channels, we employed calcium imaging. In the first series 
of experiments, cultured trigeminal neurons of C57BL/6 
mice were challenged with phenylephrine 30 mM for 1 min, 
followed by agonists of three TRP channels, TRPM8 (in the 
majority of experiments), TRPA1 and TRPV1. The selective 
TRPM8 agonist WS‐12 (5  µM) was applied 90  s after 
phenylephrine for 30 s, 4 min later the TRPA1 agonist allyl 
isothiocyanate (AITC) 100 M was applied for 1 min, followed 
after 3 min by the selective TRPV1 agonist capsaicin 1 M for 
20 s (Figure 4a). Finally, a fully depolarizing concentration 
of KCl (60 mM) was applied for 30 s. Phenylephrine elicited 
robust calcium transients in 58 of 393 C57BL/6 TG neurons 
(14.8%). In this whole sample of 393 cells, 202 (51.4%) 
responded to AITC and 177 (45.0%) responded to capsaicin, 
which is generally in agreement with published data about the 
fractions of TRPA1 and TRPV1 expressing cells, respectively 
(Akopian, Ruparel, Jeske, & Hargreaves, 2007). In a sample 
of 221 cells also tested with the TRPM8 agonist WS‐12, 
25 (11.3%) were responsive (Figure 4a). 37 (63.8%) of the 
58 phenylephrine‐sensitive neurons, responded to AITC 
and 50 (86.2%) to capsaicin. Of 37 phenylephrine‐sensitive 
neurons, 10 proved to be WS‐12‐sensitive (27%). All neurons 
responded to KCl (60 mM), which was finally superfused for 
30 s as a depolarizing control.
To investigate the possible contribution of the increased 
osmolarity of the phenylephrine stimulus (30 mM), we car-
ried out a control experiment on mouse (C57BL/6) trigem-
inal neurons, in which a total of 135 cells were stimulated 
with mannitol (90 mM; 1 min), followed by phenylephrine 
(30 mM; 1 min), capsaicin (1 µM; 30 s) and KCl (50 mM; 
30 s) (Figure 4b). Of these neurons, only 12 (8.9%) responded 
to the hyperosmotic stimulus (mannitol), with relatively 
small calcium increases. In contrast, phenylephrine activated 
44 neurons (32.6%), only six of which responded to mannitol. 
Of the 44 phenylephrine‐sensitive neurons 34 (77.3%) were 
also activated by capsaicin, revealing a high co‐expression of 
TRPV1 among phenylephrine‐responding neurons.
In another series of experiments the effect of the TRPV1 
antagonist BCTC (1 M) on the response of trigeminal neurons 
of two C57BL/6 mice to phenylephrine (30 mM) was tested. 
Phenylephrine was first applied for 1 min in the presence of 
BCTC (BCTC was pre‐applied for 1 min); then after 3 min 
phenylephrine was applied alone for 1 min. After 4 min, cap-
saicin (1 M) was applied for 20 s and finally, after another 
3  min, KCl (60  mM) for 30  s. In the presence of BCTC, 
F I G U R E  4  Calcium imaging of dissociated trigeminal 
ganglion (TG) neurons from mice. (a) Calcium transients (change in 
fluorescence ratio) in seven C57BL/6 TG neurons, represented by 
different colours, as a response to phenylephrine (Phe, 30 mM), the 
TRPM8 agonist WS‐12 (5 µM), the TRPA1 agonist AITC (100 µM), 
the TRPV1 agonist capsaicin (CAP, 1 µM) and depolarizing KCl 
(60 mM). (b) Averaged calcium transient responses of 135 TG neurons 
stimulated with mannitol (90 mM; 1 min), followed by phenylephrine 
(30 mM; 1 min), capsaicin (1 µM; 30 s) and KCl (50 mM; 30 s). 
(c) Relative responses (maximal change in fluorescence ratio ΔR/
baseline ratio R0) of 22 C57BL/6 neurons to phenylephrine (Phe) in 
the presence (black circles) and in the absence (open circles) of the 
TRPV1 antagonist BCTC
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the response to phenylephrine was significantly reduced by 
71.5% (from 1.13 ± 0.19% to 0.32 ± 0.14%, mean ± SEM, 
n  =  22, two‐tailed Student's paired t test, p  <  .01, Figure 
4c). In this experiment, the fraction of phenylephrine‐sen-
sitive cells was 20.8% (22 of 106), whereas 56.6% of cells 
responded to capsaicin (60 of 106). Sixteen of the 22 phen-
ylephrine‐responding cells were capsaicin‐sensitive (72.7%). 
Interestingly, in all six phenylephrine‐sensitive neurons not 
responding to capsaicin, the response to phenylephrine was 
also inhibited by BCTC.
In TG neurons of two TRPV1‐/‐ mice, the fraction of phen-
ylephrine‐sensitive cells was significantly reduced to 5.2% (7 
of 134, Fisher exact probability test p < .05 compared to WT; 
Figure 5a). In the sample of 134 TRPV1‐/‐ TG neurons, 55 
(41%) were activated by AITC and only 2 (1.5%) responded 
to capsaicin, confirming genetic ablation of the capsaicin re-
ceptor, TRPV1. Four (57.1%) of the 7 TRPV1‐/‐ phenyleph-
rine‐sensitive neurons were activated by the TRPA1 agonist 
AITC and none by capsaicin. All neurons responded to KCl 
(60 mM) superfused for 30 s at the end of the experiment.
F I G U R E  5  (a) Averaged calcium 
transient responses of 172 WT and 134 
TRPV1‐/‐ TG neurons to phenylephrine, 
AITC, capsaicin and KCl. Dotted lines 
indicate SEM. (b) Calcium imaging of 
HEK293T cells expressing hTRPV1. 
Averaged calcium responses of cells 
stimulated twice with phenylephrine (Phe, 
30 mM) and capsaicin (Cap, 200 nM) under 
control conditions (black traces) and in the 
presence of BCTC (5 µM) during the second 
phenylephrine application (red traces). After 
wash‐out of phenylephrine/BCTC, cells 
responded to capsaicin, although at a lower 
extent compared to the control. Data are 
presented as mean (continuous lines) ± SEM 
(dotted lines)
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Finally, phenylephrine was tested on recombinant hTRPV1 
receptor channels expressed in HEK293T cells. Phenylephrine 
(30 mM) applied twice for 1 min at an interval of 3 min acti-
vated 47 of 157 capsaicin‐sensitive cells (presumably express-
ing hTRPV1). Interestingly, the second response appeared 
higher compared to the first, suggesting sensitization (Figure 
5b). Following the removal of phenylephrine the calcium in-
crease evoked by the drug did not return completely to baseline, 
indicating sustained activation of the receptor. In the presence 
of the TRPV1 antagonist BCTC (5 µM) applied together with 
the second application, the response to phenylephrine was com-
pletely abolished in hTRPV1‐expressing HEK293T cells.
3.4 | Meningeal blood flow
In pilot experiments, phenylephrine was topically applied at 
concentrations of 1 µM, as well as 30 and 100 mM, and from 
the variance of blood flow changes a statistically evaluable 
group size of n = 8 was calculated. In the main experiments, 
phenylephrine was applied at increasing concentrations 
(1  µM‐100  mM) for 5  min each, separated by washout 
periods of 10 min, during which the meningeal blood flow 
returned to the pre‐application level. Phenylephrine at 
1 µM failed to influence blood flow (0.4 ± 1.1% increase; 
n = 8, t‐test), whereas the concentrations of 10 µM‐3 mM 
significantly reduced the flow compared to baseline. The 
most powerful decrease in flow was measured at 1  mM 
concentration (−18.1 ± 3.8%; n = 21, Wilcoxon, p < .001). 
In contrast, topical applications of phenylephrine at 10 – 
100 mM elicited increases in meningeal blood flow, which 
were statistically significant at the two highest phenylephrine 
concentrations, that is at 30 and 100  mM (12.5  ±  2.7%, 
n = 29 and 21.3 ± 4.1%, n = 25, respectively; t‐test, p < .005 
and < 0.001) (Figure 6a).
The systemic blood pressure of the animals was 
103.6  ±  3.4  mmHg. Applications of phenylephrine at 
F I G U R E  6  (a) Changes in 
meningeal blood flow induced by topical 
application of different concentrations 
of phenylephrine onto the exposed dura 
mater. (b) Changes in meningeal blood flow 
induced by phenylephrine (30 mM) without 
pretreatment, after blocking CGRP receptors 
with CGRP8‐37 (100 µM) and TRPV1 
receptors with BCTC (10 µM). The box plot 
diagram with 25/75% interquartile range 
shows median (line), mean (square dot) 
and variation in values. Flow values before 
and after application of phenylephrine (a) 
or after phenylephrine with and without 
pretreatment (b) were compared using the 
Student’s t‐test;* significant difference
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1 µM–3 mM concentrations failed to influence the blood 
pressure, whereas phenylephrine at 10 – 100 mM induced 
some increase in pressure. For further blood flow mea-
surements the 30 mM concentration of phenylephrine was 
chosen, because it induced a robust blood flow increase 
without increasing arterial blood pressure significantly. 
After 30 mM phenylephrine the arterial pressure increased 
on average by 8.7 ± 2.2% (Wilcoxon, p < .001) during the 
5 min application period. However, there was no correlation 
between the changes in arterial pressure and the changes in 
blood flow (r = −0.18, p > .05; product‐moment correla-
tion). In experiments with visible changes in arterial blood 
pressure, these were limited to the first 3  minutes of the 
dural phenylephrine application, whereas increases in men-
ingeal blood flow were present throughout the whole 5 min 
application period.
In pilot experiments, the blocking effect on the phenyl-
ephrine‐induced (30 mM) blood flow increase was tested, 
and from the variance of measurements a statistically eval-
uable group size of n  ≥  10 was calculated. In the main 
experiments, blocking the CGRP receptors by pre‐applica-
tion of 100 µM CGRP8‐37 to the dura mater significantly 
inhibited the phenylephrine‐induced blood flow increase 
(2.3  ±  6.3%; n  =  10, t‐test, p  <  .05). Next we aimed to 
clarify the role of chemosensitive nociceptors in the dura 
mater, which are known to release CGRP upon their acti-
vation causing arterial vasodilatation and increased blood 
flow. The majority of these nociceptive afferents express 
TRPV1 receptor channels. Pretreatment of the dura mater 
with the TRPV1 receptor antagonist BCTC at 10 µM sig-
nificantly inhibited the phenylephrine‐induced increase in 
meningeal blood flow (4.9 ± 2.0%; n = 10, t‐test, p < .05) 
(Figure 6b). Together with the data from the CGRP release 
and the calcium imaging, these results argue for a role of 
TRPV1 rather than TRPA1 receptors in the phenylephrine‐
induced blood flow increase.
4 |  DISCUSSION
The present experiments show that high concentrations 
(≥ 30 mM) of the α1‐adrenoceptor agonist phenylephrine 
activate trigeminal neurons in rodent models of trigeminal 
nociception. This activation is indicated by CGRP release 
from peptidergic afferents upon calcium inflow and, as 
neurovascular consequence of the neuropeptide release, 
increase in meningeal blood flow. It is very unlikely that 
this activation is due to the high molarity of phenylephrine, 
since mannitol at 90 mM did neither cause CGRP release 
nor an effective increase in intracellular calcium. The 
experiments also showed that the responses to high‐dose 
phenylephrine are independent of α1‐adrenoceptors, 
although these adrenoceptors seem to be expressed in some 
trigeminal neurons innervating the dura mater, albeit very 
rarely co‐localized with CGRP. Instead, the responses seem 
to depend mainly on the activation of TRPV1 receptor 
channels but not on TRPA1 receptor channels, because 
phenylephrine‐induced responses present in HEK293T 
cells transfected with hTRPV1 are largely suppressed by 
inhibiting TRPV1 and are nearly, though not completely, 
absent in animals with genetically deleted TRPV1 
receptors.
4.1 | Major role for TRPV1 
receptors in phenylephrine‐induced 
trigeminal nociception and pain
TRPV1 receptor channels are expressed in a major pro-
portion of nociceptive afferents, constituting the crucial 
molecular transduction channels for a variety of noxious 
stimuli associated with painful tissue lesions, inflamma-
tion and heat (Holzer, 2008; Rosenbaum & Simon, 2007; 
White, Urban, & Nagy, 2011).The unexpected finding that 
high‐dose phenylephrine is obviously also an agonist at 
TRPV1 receptors, including human TRPV1, cannot eas-
ily be explained by its molecular structure, although it has 
some similarity with the aromatic end‐structure of capsai-
cin. Phenylephrine at high concentrations is routinely used 
as a mydriatic agent and for the treatment of nasal con-
gestions (https ://medli neplus.gov/drugi nfo/meds/a6160 
49.html) frequently causing transient local burning or 
stinging pain sensations (Moisseiev et al., 2015). We now 
offer a reasonable pathophysiological explanation for these 
effects, which are reminiscent of mild capsaicin‐evoked 
pain. There are few other reports suggesting an involve-
ment of TRPV1 in pronociceptive effects of phenylephrine. 
Subcutaneous injection of phenylephrine (2.5 mg/kg, daily 
for 2 weeks) in rodents induced abdominal mechanical hy-
peralgesia, which was absent in TRPV1‐/‐ mice (Matos et 
al., 2016); however, pain behaviour was also reversed by 
a selective α1A‐adrenoceptor antagonist. Injection of phe-
nylephrine (0.1–10  µM) in human skin dose‐dependently 
decreased heat pain threshold but not mechanical pain 
threshold (Fuchs, Meyer, & Raja, 2001), which would be 
in line with the sensitization of TRPV1 receptor channels.
Beyond the transient character of TRPV1 opening, an ef-
fective activation of TRPV1 receptors followed by massive 
calcium inflow causes insensitivity to repeated application of 
the agonists (tachyphylaxis) (Touska, Marsakova, Teisinger, 
& Vlachova, 2011) and finally long‐lasting inactivation of the 
neuron, most likely due to a permanent depolarization block, 
as it was described for the slowly acting but highly effective 
TRPV1 agonist resiniferatoxin (Raisinghani, Pabbidi, & 
Premkumar, 2005). Phenylephrine at high doses seems to act 
similarly at TRPV1 receptors and thus may lead to a long‐last-
ing depolarization of trigeminal neurons. Thus neuropeptide 
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release upon depolarizing KCl, which depends primarily on 
the opening of voltage‐sensitive calcium channels (Kress, 
Izydorczyk, & Kuhn, 2001), seems to be dose‐dependently 
blocked after 10 min treatment with high‐dose phenylephrine 
(see Figure 2b). In our calcium‐imaging experiments neurons 
responding vigorously to capsaicin showed a long‐lasting 
calcium signal and responded only weakly to depolarizing 
KCl (see Figure 4a). Besides, the CGRP secreting sensory 
fibres in the cranial dura mater seem to be more effectively 
activated by phenylephrine compared to the dissociated neu-
rons and intact ganglia, which after phenylephrine treatment 
for 10 min still responded to KCl with some calcium signal 
or neuropeptide release, respectively (compare Figure 3b and 
3c). This difference may be due to a higher calcium buffer 
capacity and larger neuropeptide stores of the cell somata 
compared to the thin peripheral nerve fibres. However, we 
cannot explain the observation that, after phenylephrine in 
the presence of the TRPV1 receptor blocker BCTC, KCl was 
again ineffective in releasing CGRP from rat dura mater (see 
Figure 3a). It may be speculated that high‐dose phenyleph-
rine has also an inhibitory effect on voltage‐gated calcium 
channels independent of TRPV1.
Headache is another, yet mechanistically unexplained, 
side‐effect of phenylephrine noted in instruction leaflets 
of drugs containing phenylephrine for local (ocular, nasal) 
application (https ://www.webmd.com/drugs/ 2/drug-6979/
pheny lephr ine-ophth almic-eye/details) (https ://medli 
neplus.gov/drugi nfo/meds/a6160 49.html). This type of 
headache is not well defined in the literature and not specif-
ically listed in the International Classification of Headache 
Disorders, third edition (ICHD‐3) (Headache Classification 
Committee of the International Headache Society (IHS), 
2013) , where it could be classified at its best into category 
8.1.9 of secondary headaches (‘Headache attributed to oc-
casional use of non‐headache medication’). It is generally 
assumed that headaches involve the activation of intracra-
nial afferents of the trigeminal nerve and/or the second 
order neurons in the spinal trigeminal nucleus, where these 
afferents are projecting to (Levy, Labastida‐Ramirez, & 
MaassenVanDenBrink, 2018; Olesen, Burstein, Ashina, & 
Tfelt‐Hansen, 2009; Schueler, Messlinger, Dux, Neuhuber, 
& Col, 2013). Headache and ocular pain are frequently as-
sociated (Dafer & Jay, 2009), and there is a close associa-
tion between nasal/paranasal lesions and headaches (Pinto, 
Rossi, McQuone, & Sollecito, 2001; Silberstein, 2004). The 
effectivity of intranasal application of drugs for the treat-
ment of headaches is supportive for this view (Rapoport, 
Bigal, Tepper, & Sheftell, 2004). Possibly intranasal phen-
ylephrine reaches directly the meninges by‐passing the 
blood brain barrier, as it has been discussed for triptans 
(Rapoport & Winner, 2006). We assume that phenyleph-
rine is able to diffuse along the fila of the olfactory neurons 
through the lamina cribrosa to reach the meninges directly 
on this route, as it was shown for other substances. For ex-
ample nasal application of irritants such as capsaicin can 
activate meningeal afferents either directly or via a para-
sympathetic reflex, which seem to work at least partially 
via this nasal‐meningeal pathway (Gottselig & Messlinger, 
2004; Kunkler, Ballard, Oxford, & Hurley, 2011). Another 
hypothesis has very recently been proposed (Zhang, 
Kunkler, Knopp, Oxford, & Hurley, 2019). The authors 
have found upregulation of TRPA1 mRNA in trigeminal 
ganglion neurons specifically innervating the dura mater 
after chronic exposure of rats to an atmosphere containing 
the TRPA1 agonist acroleine. They suggest an intragangli-
onic transmission from neurons innervating the nasal mu-
cosa to neurons innervating the meninges. Irrespective of 
these proposed mechanism, inhalation of chemical irritants 
(e.g. acrolein, formaline) can induce headaches in suscepti-
ble persons by stimulating TRP receptors of the nasal mu-
cosa (Kunkler, Zhang, Johnson, Oxford, & Hurley, 2018).
4.2 | Possible role for other TRP receptor 
channels and α1‐adrenoceptors
Another TRP receptor channel responding to a big variety of 
endogenous and exogenous chemical substances is TRPA1 
(Koivisto et al., 2014; Nilius, Appendino, & Owsianik, 2012). 
We originally speculated that it may be involved in the phe-
nylephrine effects but blockade by the specific TRPA1 antag-
onist, HC030031, was ineffective in reducing CGRP release. 
In contrast, the specific blockade of TRPV1 with BCTC was 
very effective in inhibiting neuropeptide release, which was 
finally confirmed in mice lacking functional TRPV1 recep-
tors (see Figure 3a‐c). However, an additional mechanism, by 
which high‐dose phenylephrine can activate sensory neurons, 
cannot be excluded, because in the calcium imaging experi-
ments the overlap of the responses to capsaicin and phenyle-
phrine was not complete: roughly 80% of neurons responding 
to phenylephrine responded also to capsaicin, whereas some 
neurons were still activated by phenylephrine in the presence 
of BCTC (see Figure 4c).
We can also not exclude that phenylephrine causes cal-
cium signals in trigeminal neurons without releasing neu-
ropeptides, possibly by activation of α1‐adrenoceptors, 
immunoreactivity of which was found in a minor percentage 
of trigeminal ganglion neurons and in perivascular nerve fi-
bres of the dura mater. The expression of α1‐adrenoceptors 
has already been described in myelinated and unmyelinated 
sensory nerve fibres, but not in sympathetic fibres, in rat 
skin (Dawson, Phillips, Finch, Inglis, & Drummond, 2011). 
The expression of α1‐adrenoceptor has been confirmed in 
dorsal root ganglia, where double labelling showed co‐ex-
pression within sub‐populations of CGRP, IB4 and TRPV1 
immunoreactive neurons. Following chronic constriction 
injury, the expression of α1‐adrenoceptors in rat cutaneous 
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nociceptors was found increased (Drummond, Dawson, 
Finch, Bennett, & Drummond, 2014). The authors sug-
gested that this may contribute to the sensory‐sympathetic 
coupling increasing the sensitivity to adrenergic agonists 
after nerve injury.
4.3 | Vascular effects of phenylephrine
In our in vivo experiments blood flow measurements 
showed decreased meningeal blood flow after the applica-
tion of lower phenylephrine concentrations indicating arte-
rial vasoconstriction, whereas high concentrations increased 
meningeal blood flow. Activation of several subtypes of 
vascular α1‐adrenoceptors constricts blood vessels leading 
to reduction in blood flow (Civantos Calzada & Aleixandre 
de Artiñano, 2001). The mechanism is explained by the ac-
tivation of the receptor coupled G‐protein Gq/11 followed 
by phospholipase C and inositol phosphate (IP) turnover 
and the opening of IP3‐sensitive Ca2+ channels of intracel-
lular calcium stores (Docherty, 2010), which is controlled 
by L‐type voltage‐gated Ca2+ channels of the cell mem-
brane (Leloup, Hove, Meyer, Schrijvers, & Fransen, 2015). 
In human pial arteries both α1‐ and α2‐adrenoceptors have 
been found by radioligand‐binding studies (Ferrari‐DiLeo 
& Potter, 1985). In isolated feline middle cerebral artery, 
the α2‐adrenoceptor agonist clonidine was much more po-
tent than the α1‐adrenoceptor agonist phenylephrine, sug-
gesting the preferential expression of α2‐adrenoceptors 
(Skärby, Andersson, & Edvinsson, 1983), but this is not 
clear for dural arteries. The high sensitivity to phenyle-
phrine of meningeal blood flow may indicate the preferen-
tial action of α1‐adrenoceptors in rat dura mater. According 
to our immunostainings, α1‐adrenoceptors are expressed in 
precapillary dural blood vessels, which can regulate blood 
flow very effectively (see Figure 1b). However, at high 
concentrations of phenylephrine activation of trigeminal 
TRPV1 receptors leading to CGRP release and consequent 
increase in meningeal blood flow is apparent and overrides 
the α‐adrenoceptor‐induced constriction.
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